Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Up 57.8% in January

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) was the target of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 644,912 shares, an increase of 57.8% from the January 15th total of 408,588 shares. Based on an average trading volume of 246,539 shares, the days-to-cover ratio is presently 2.6 days. Currently, 2.0% of the shares of the company are sold short. Currently, 2.0% of the shares of the company are sold short. Based on an average trading volume of 246,539 shares, the days-to-cover ratio is presently 2.6 days.

Institutional Trading of Oramed Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. BML Capital Management LLC grew its position in Oramed Pharmaceuticals by 2.1% in the second quarter. BML Capital Management LLC now owns 3,083,253 shares of the biotechnology company’s stock valued at $6,937,000 after acquiring an additional 62,505 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Oramed Pharmaceuticals during the 4th quarter valued at approximately $738,000. Jane Street Group LLC increased its position in Oramed Pharmaceuticals by 31.2% during the 4th quarter. Jane Street Group LLC now owns 78,259 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 18,600 shares in the last quarter. HRT Financial LP acquired a new position in Oramed Pharmaceuticals during the 4th quarter worth approximately $131,000. Finally, Bank of America Corp DE boosted its position in Oramed Pharmaceuticals by 4.4% in the third quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock valued at $395,000 after buying an additional 6,261 shares in the last quarter. 12.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Oramed Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen raised Oramed Pharmaceuticals to a “hold” rating in a research report on Saturday, November 1st. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, Oramed Pharmaceuticals presently has a consensus rating of “Hold”.

Oramed Pharmaceuticals Trading Up 2.5%

Shares of NASDAQ:ORMP opened at $3.25 on Friday. The firm has a 50 day moving average of $3.22 and a 200-day moving average of $2.65. Oramed Pharmaceuticals has a 12 month low of $1.82 and a 12 month high of $3.71. The stock has a market capitalization of $129.35 million, a PE ratio of 2.58 and a beta of 1.34.

Oramed Pharmaceuticals Announces Dividend

The firm also recently announced a dividend, which was paid on Monday, January 26th. Shareholders of record on Friday, January 16th were paid a dividend of $0.25 per share. The ex-dividend date was Friday, January 16th. Oramed Pharmaceuticals’s dividend payout ratio is presently 19.84%.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.